Traws Pharma, Inc. Proceeds from Long-Term Debt Issued
Traws Pharma, Inc. (TRAW) reported Proceeds from Long-Term Debt Issued of $25.82 million for the 12-month period ending 2012-12-31, per its 10-K filed 2015-03-30.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2015-03-30
- Traws Pharma, Inc. proceeds from issuance of long-term debt for the quarter ending 2012-12-31 was $0.00.
- Traws Pharma, Inc. proceeds from issuance of long-term debt for the quarter ending 2012-09-30 was $16.34M.
- Traws Pharma, Inc. proceeds from issuance of long-term debt for fiscal 2012 was $25.82M, a 4065.16% increase from fiscal 2011.
- Traws Pharma, Inc. proceeds from issuance of long-term debt for fiscal 2011 was $620.00K.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-30 | $16.34M derived: sum of 2 quarters · filed 2015-03-30 | $25.82M 10-K · filed 2015-03-30 | |
| 2012-09-30 | $16.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | $25.82M 10-Q · filed 2013-11-14 | ||
| 2012-06-30 | $9.49M 10-Q · filed 2013-09-06 | |||
| 2011-12-31 | $620.00K 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |